<?xml version="1.0" encoding="UTF-8"?>
<p id="par0045">Nevertheless, a timely identification of the two co-infections is needed in relation to difference in treatments and prognosis. Antiviral therapy is currently available for influenza infection (i.e. oseltamivir, zanamivir, and peramivir) while experimental off-label drugs (i.e. lopinavir/ritonavir, chloroquine, and hydroxychloroquine) have been commonly used in COVID-19 treatment. In particular, the boosted protease inhibitor lopinavir/ritonavir has been previously associated with significantly fewer adverse clinical outcomes for the treatment of SARS and furthermore, in association with the Interferon Beta-1b, it has been demonstrated to be beneficial in animal studies against the Middle East Respiratory Syndrome (
 <xref rid="bib0035" ref-type="bibr">Chu et al., 2004</xref>, 
 <xref rid="bib0020" ref-type="bibr">Chan et al., 2015</xref>). Considering the severity of the clinical picture and the prompt availability of lopinavir/ritonavir in our Institute, clinicians opted for this treatment although the antiviral effects remain to be determined (
 <xref rid="bib0015" ref-type="bibr">Cao et al., 2020</xref>).
</p>
